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Vaccine Preventable 
Diseases: A Re-emerging Threat
A digitally-colorized scanning electron micrograph (SEM) 
depicts a blue-colored, human white blood cell interacting 
with two pink-colored, rod-shaped, multidrug-resistant (MDR) 
Klebsiella pneumoniae bacteria. Credit: David Dorward; PhD; 
National Institute of Allergy and Infectious  Diseases (NIAID) 
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Vaccines are one of the most effective public health interventions that has ever been 
employed. Routine use of vaccines has significantly reduced or eliminated many previously 
common childhood vaccine preventable diseases (VPDs) in the US. However, increased 
globalization and a reluctance to follow the recommended vaccination schedule in certain 
populations, has led to more common outbreaks of VPDs that had once been rare, such 
as measles or whooping cough. The years 2013 and 2014 saw outbreaks of increased 
frequency and size.
Measles
In 2013, there were 11 measles1 outbreaks and 503 cases,2 while the Centers for Disease 
Control and Prevention (CDC) reported nearly 300 confirmed cases of measles in the first 
half of 2014 alone.3 Outbreaks in 2013 and the beginning of 2014 occurred in many states 
including North Carolina, Texas, Massachusetts, California, Ohio and Washington. The outbreak 
sizes ranged from small outbreaks of three cases to large outbreaks of over 100 cases.3,4  
Mumps
In 2013, CDC received reports of 438 cases of mumps from 39 states. The first half of 2014 
has seen 871 cases, more than double the number of mumps cases reported to CDC in 
2013.5,6 These cases involved four large outbreaks originating on four different university 
campuses, including those in Ohio, Wisconsin and New York City.5,6 Outbreaks ranged from 
three cases to over 300 cases5 in 2013 and the first half of 2014.  
Bordetella pertussis 
While rates of B. pertussis in the United States decreased from 2012–2013, 13 states 
reported an increase in cases in 2013 and  large outbreaks have occurred in California, 
Ohio, Texas, Washington, Wisconsin and Minnesota.7,8 There has been a 30% increase of B. 
pertussis cases reported to CDC in the first half of 2014 compared to the same time period 
of 2013.9 Additionally, in the first half of 2014, 27 states reported an increase in cases 
compared to the same time period in 2013.10 
VPD Public Health Laboratory 
Reference Centers:
Identifying the Need
Photomicrograph of Haemophilus influenzae using immunofluorescence. Credit: CDC
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“The addition of the 
VZV SNP PCR assay 
has revolutionized the 
way in which we are 
able to provide more 
precise data regarding 
VZV suspect patients. 
We can now provide 
results on whether a 
case is vaccine-related 
or is from a wild-
type strain. This has 
proved useful to testing 
specimens submitted 
from VPD project labs 
as well as our local 
laboratories.” 
~ Jill Hacker, PhD, MPH, 
California Department of Public 
Health, Viral and Rickettsial 
Disease Laboratory  
Although re-emerging in many cases, outbreaks of most VPDs are 
uncommon and routine laboratory testing for VPDs is not practical. 
This makes it difficult for every public health laboratory (PHL) to identify 
resources necessary to implement and sustain capacity for state of the 
art testing services for a broad range of VPDs. This is particularly true of 
molecular testing methods, which allow for more reliable identification of 
VPDs in the earlier days of infection. Recognizing this challenge, CDC and 
APHL established a partnership in 2010 to begin to examine gaps in VPD 
testing capabilities and identify potential solutions. 
A series of surveys, key informant interviews and stakeholder 
meetings led to the concept of establishing PHL reference centers 
that would serve a variety of functions: diagnostic testing, testing for 
surge capacity, surveillance testing, confirmatory testing, serotyping/
serogrouping, sequencing, proficiency testing and access to subject 
matter experts. In 2012, APHL and CDC selected and established four 
VPD Reference Centers (Figure 1): California Department of Public 
Health Laboratory, Minnesota Public Health Laboratory Division, New 
York State Department of Health: Wadsworth Center and Wisconsin 
State Laboratory of Hygiene (WSLH). Laboratory staff were trained on 
CDC protocols and validated them in their own laboratories. 
The Reference Centers have been providing enhanced capacity for 
molecular and serologic testing for eight VPDs in a shared service 
model since 2013 (Table 1). Other public health laboratories enroll in 
the program voluntarily and receive the testing services at no cost to 
their laboratories or VPD programs. The WSLH also provides proficiency 
testing panels for public health laboratories choosing to offer select 
VPD services and serves as a specimen repository for VPD specimens 
that can be used for evaluation and validation of new testing methods. 
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Viral 
Diseases
Real Time 
RT-PCR Serology Genotyping
Maximum Turn 
Around Times
Measles  
PCR: 2 
days
Genotyping: 10 
Days
Mumps  
Rubella  
Varicella-zoster  
Bacterial 
Diseases Real Time PCR Serology
Serotyping/
Grouping
Maximum Turn 
Around Times
B. pertussis  
PCR: 2 
Days
Serology: 5 
Days
Serotyping/grouping: 
5 Days
S. pneumoniae  
N. meningitidis  
H. influenzae  
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Figure 1: VPD Reference Centers: California and New York provide viral VPD testing services to their 
assigned submitting laboratories. Minnesota provides bacterial and viral VPD testing services to their 
submitting laboratories. Wisconsin provides bacterial and viral VPD testing services and serves as a 
Performance Evaluation Center and holds a VPD specimen repository.
Table 1: Vaccine Preventable Disease Reference Center Test Menu
Genotyping: Genotyping will be performed on all PCR positive specimens unless otherwise indicated 
as a part of a larger outbreak.
*S. pneumoniae: At this time the Bacterial VPD Reference Centers will only accept S. pneumoniae 
specimens or isolates from children ≤5 years old with history of vaccination (PCV13 or PPSV23)
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The First Year of Testing: 2013–14
From April 22, 2013 to June 30, 2014, the VPD Reference Centers received 567 specimens 
from enrolled submitting laboratories and performed over 800 VPD tests. A total of 46 
PHLs (Figure 2), 36 state PHLs and 10 local PHLs, were enrolled as submitting sites as of 
June 30, 2014. The VPD Reference Centers have assisted in testing for six VPD outbreaks 
in the first year. Results are routinely reported to the submitting site within 24 hours of 
specimen receipt for PCR requests and within 3-5 days for further characterization. In 
addition to reporting the results to the submitter, the Reference Centers also report results 
for specimens tested to CDC via electronic HL7 messaging or a secure FTP site (Figure 3).  
This messaging of results to CDC does not replace state notifications to CDC through the 
Nationally Notifiable Diseases Surveillance System.  
This report further describes the testing performed at the Reference Centers during the 15 
months and includes accounts of success stories from Reference Centers and their submitters.  
Figure 2: As of June 30, 2014, 46 (36 state and 10 local) public health laboratories were enrolled as VPD 
Submitting Sites.  
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Figure 3: Flow Diagram of the Specimen Submission Process: Once notified of a potential VPD 
case, appropriate specimens are collected by clinicians and sent to the enrolled submitting site. 
The submitting site then contacts their assigned Reference Center and prepares the specimen for 
shipping with the appropriate requisition form. When the specimen is received by the Reference 
Center, it is tested and results are promptly reported back to the submitting site. Viral RT-PCR results are 
routinely reported within 24 hours of specimen receipt.  
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informs 
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laboratory ships 
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a completed 
submission form
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Reference 
Center receives 
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Results are 
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Results are 
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submitting 
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Results are 
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appropriate 
epidemiologist 
by the submitting 
laboratory
Specimen 
Submission 
Process 
Experiences of the VPD 
Reference Centers
California Department of Public Health, Public Health Laboratories in Richmond, CA
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California Department of Public Health 
Viral and Rickettsial Disease Laboratory
Rubella was declared eliminated in the US in 2002, yet cases continue to occur due to 
importation. Far fewer cases of rubella are reported annually, with a national range of 3-10 
cases per year (0 to 2 in California) from 2009-2013. Because the clinical presentation of 
measles and rubella can be similar, the Reference Centers reflex all PCR-negative suspect 
measles cases for rubella testing. At CDPH VRDL, specimens submitted for measles PCR are 
tested simultaneously for both viruses. 
Using the concurrent testing approach, rubella was identified in two 
cases reported as suspect measles. In May, real-time PCR identified 
rubella in an adult male traveler from India. One month later, the 
same approach detected rubella in an adult female traveler from 
Afghanistan. The female case was not pregnant and neither case had 
known contact with pregnant women. These were the first cases of 
rubella in California since 2012. Both cases were genotype 2B, and 
no additional rubella cases were identified. These cases highlight the 
utility and benefit of concurrent measles and rubella PCR testing.
The CDPH VRDL 2014 experience with measles and rubella has 
highlighted the important role of swift laboratory confirmation in 
the investigation of both of these diseases. With a disease as highly 
infectious as measles, rapid availability of laboratory data permits 
epidemiologists to focus their investigative efforts on known cases 
and their contacts, particularly high risk contacts who may urgently 
need post-exposure prophylaxis. 
Similarly, detection of a case of rubella facilitates the identification 
of exposed pregnant women whose infants may be at risk for 
congenital rubella syndrome. With the established standardized 
genotyping methods, the VPD Reference Centers provide molecular 
epidemiological data that have proved invaluable in responding to 
cases and outbreaks and generate useful genotyping data for future 
strain comparisons. 
“Over the course of 
the last 12 months, 
ASVL has submitted 
27 samples to our 
designated APHL/CDC 
Vaccine Preventable 
Disease Reference Lab 
in Richmond, California. 
Communication and 
TAT’s have been 
superior.”  
~ Bonnie Bond, Virology 
Manager, Alaska Division of Public 
Health Laboratory  
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CDPH VRDL VPD Team: Back row (from left): Chris Preas, Ashraf Fadol, Chris Anderson, Oliver Oyler, Anthony 
Moore. Seated: Alex Espinosa, Regina Chase, Jill Hacker, Dongxiang Xia, Abiy Tadesse, Carlos Gonzalez. Not 
shown: Giorgio Cosentino, Natasha Espinosa
Ashraf Fadol testing a VPD specimen
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Figure 4: Viral Testing by the Numbers: Viral VPD tests performed at the VPD Reference Centers April 
22, 2013-June 30, 2014. The graph above depicts the testing performed at the four viral VPD Reference 
Centers: the California Department of Public Health, New York State: Wadsworth Center, the Minnesota State 
Department of Health and the Wisconsin State Laboratory of Hygiene. The data includes only submissions 
from enrolled submitting sites.  
Figure 5: Viral VPD Testing Performed by Month: The graph above depicts the testing performed at the four viral VPD 
Reference Centers: the California Department of Public Health, New York State: Wadsworth Center, the Minnesota 
State Department of Health and the Wisconsin State Laboratory of Hygiene. The Reference Centers began 
accepting specimens on April 22, 2013. The data includes only submissions from enrolled submitting sites. Spikes 
in the testing numbers correlate with several outbreaks.
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Patrick Bryant, PhD from the New York Department of Health: Wadsworth Center
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New York State Department of Health, 
Wadsworth Center
Wadsworth Center Congenital Rubella Case
In December of 2013, the Wadsworth Center 
Virology Laboratory received specimens collected 
from a newborn in Erie County with suspected 
congenital rubella syndrome (CRS). At this time, the 
newborn was being kept in isolation in the NICU in 
Erie County with symptoms consistent with CRS. 
The patient’s mother also had travel history to 
Yemen and an undetermined vaccination history. 
Fortunately, the Wadsworth Center had recently 
begun a new collaboration with the CDC and 
APHL as a reference center for APHL’s Vaccine 
Preventable Disease Project. The Wadsworth 
Center Virology Laboratory, with the assistance 
of CDC, recently established CDC’s Rubella real-
time RT-PCR assay and conventional RT-PCR 
typing assays for the detection and genotyping of 
rubella in the laboratory. As a result, the Virology 
Laboratory was able to perform testing on a throat 
swab, NPS and Urine from the newborn, all of which 
were positive by real-time RT-PCR. Genotyping by 
sequencing determined the genotype to be 1E, 
which has a large global distribution and is often 
associated with CRS. 
A further detailed phylogenetic analysis performed 
by CDC determined that the rubella sequence 
generated by the Virology Laboratory was most 
closely related to two rubella specimens that 
had been isolated in Yemen in 2008. The infant 
was placed in isolation in the family home and 
continues to be monitored for viral shedding by the 
Virology Laboratory. As of May 14, 2014, samples 
collected from the infant were still testing positive 
for rubella, however, on July 11, 2014 an NPS 
sample collected on the child was negative.      
“Kentucky DLS has been sending 
specimens to the New York State 
Department of Health in conjunction with 
APHL/CDC’s Vaccine Preventable Disease 
Research Center Project. Since enrolling 
in the program, we have sent close to 10 
specimens for measles or mumps PCR 
testing and have received reports within 3 
days. Obviously, a much better turnaround 
time than what we could accomplish with 
culture testing.  I have gained access to 
their LIS test ordering and result retrieval 
portal which enhances their ability to assist 
us. Overall, this program has been very 
useful and the testing has been rapid, 
which has aided disease diagnosis for the 
citizens of the Commonwealth of Kentucky. 
We greatly appreciate the help!” 
~ Mathew Johnson, Virology Supervisor, Kentucky 
Department of Public Health, Public Health Laboratory  
Minnesota Department of Health, Public Health Laboratory 
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Minnesota Department of Health 
Public Health Laboratory
In September 2013, the Minnesota Department 
of Health (MDH) received a request from APHL 
that MDH add the Texas Department of Health 
as a laboratory that submits specimens to MDH 
for VPD testing. Within hours of the request, 
MDH was communicating with Texas. Texas had 
a suspect measles case that needed testing as 
soon as possible. MDH received the specimen 
the following day by overnight delivery and 
immediately tested the sample. By the end of 
the day, testing revealed that the specimen was 
positive for measles virus. MDH immediately 
notified the Texas Department of Health so they 
could begin conducting their investigation. 
The measles virus is extremely easy to pass 
from an infected person to a susceptible person. 
During the investigation of the case, the Texas 
Department of Health determined that the 
case spent time at a large Texas-based church 
that had a lot of unvaccinated members. The 
affected church’s leadership communicated with 
members to strongly encourage unvaccinated 
individuals to get vaccinated. 
Rapid testing and communication of results was 
critical for identification of a case and prevention 
of future illness. Over the course of this outbreak 
investigation, MDH tested 45 samples, nine of 
which were positive for measles by RT-PCR. 
 
“Texas began using the APHL/CDC VPD 
Reference Centers in 2013 in the middle of 
a measles outbreak. Our reference center, 
Minnesota, was able to provide for all of our 
PCR testing needs during the outbreak and 
has continued to meet our needs ever since. 
Minnesota almost always provides measles 
PCR results the same day as specimen 
receipt, which is critical when trying to decide 
whether to mount a vaccination clinic or 
not! Our contact at Minnesota (Dave) has 
also been extremely helpful (and nice!) in 
answering our questions about specimen 
submission, testing, and results, not just for 
measles but for all VPDs. We’re extremely 
grateful to have the laboratory support 
of Minnesota and the Reference Center 
project.“
~ Rachel Wiseman, MPH, Epidemiologist, Texas Division of 
State Health Services
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Applied Biosystems® ABI 7500 Real-Time PCR System used to test viral and bacterial VPD 
specimens at the Minnesota Department of Health, Public Health Laboratory 
The VPD Reference Centers have 
been successful in their primary 
goal of increasing access to quality 
molecular testing for eight VPDs.
18
Figure 6: Bacterial Testing by the Numbers: The above graph depicts the testing performed at the Minnesota 
Department of Health and the Wisconsin State Laboratory of Hygiene April 22, 2013-June 30, 2014. The data 
includes only submissions from enrolled submitting sites.  
Figure 7: Bacterial VPD Testing Performed by Month: The above graph depicts the testing performed at the 
Minnesota Department of Health and the Wisconsin State Laboratory of Hygiene by month. The data includes 
only submissions from enrolled submitting sites. In January 2014, APHL/CDC placed criteria on S. pneumoniae 
specimen submissions due to the influx of submissions in December 2013.  
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WSLH Advanced Microbiologist Jim Powell pipetting in preparation for vaccine-preventable disease testing. VPDs such as 
measles, mumps and rubella are reportable conditions in Wisconsin
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Wisconsin State Laboratory of Hygiene 
An epidemiologist at the Alabama State Health Department 
sits at her computer reviewing the reportable disease 
reports from earlier in the day when a case of pneumococcal 
meningitis in a four-year-old catches her attention. She 
immediately wonders if this is a case of vaccine failure 
or a more virulent serotype that may be circulating in the 
population. Last week, she had another case of pneumococcal 
meningitis in a three-year-old.
Epidemiologists in Alabama, an enrolled VPD submitting site, 
now have the capability to investigate these cases because 
they can take advantage of the services of their assigned VPD 
Reference Center, the Wisconsin State Laboratory of Hygiene, 
which can serotype Streptococcus pneumoniae isolates 
using molecular methods. Because many states only have a 
small number of isolates that need testing each year, it’s not 
feasible for their state public health laboratory to offer this 
testing because of the complexity and expense of the testing. 
If the isolates from these patients are vaccine strains, the 
epidemiologist will investigate if there is a possible problem 
with the vaccine such as improper storage of at the vaccination 
center and they will also offer pneumococcal vaccine to 
household members as appropriate. The serotyping results 
can also tell epidemiologists if there is a specific serotype that 
is circulating that may be causing more severe disease. 
Prior to establishment of the VPD program a little over a year 
ago, many jurisdictions could not perform this important timely 
follow up. Alabama now sends all S. pneumoniae isolates 
from vaccinated children under five years of age with severe 
pneumococcal disease to the Wisconsin State Laboratory 
of Hygiene for serotyping. At this time, epidemiologists in 
Alabama have not seen any cases of possible vaccine failure, 
but they are pleased that they now have the capability to 
detect one.
“The VPD Reference Center at 
the Wisconsin State Laboratory 
of Hygiene is phenomenal!  
They are easy to work with and 
provide immediate response 
when needed. Dave Warshauer 
and his team provide excellent 
service and a very quick turn-
around-time with results. They 
accept Saturday deliveries 
which has helped us out with 
those last minute specimens. 
The system is great and has 
given us the opportunity to 
utilize these services that we 
cannot ourselves provide to 
our citizens. We hope the VPD 
Reference Centers stay around 
for a long time.” 
~ Christi Clark, Microbiology Section 
Supervisor, West Virginia Department of 
Health and Human Resources, Office of 
Laboratory Services
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Proficiency Testing Services
Although many PHLs do not have the capacity to maintain testing for all VPDs, many 
maintain services for VPDs important to their jurisdictional public health goals. In order 
to ensure proper testing and adhere to various laboratory accrediting bodies, periodic 
checks of performance by means of proficiency or performance evaluation panels are 
required. Because VPDs are diseases of low incidence, few proficiency programs exist 
in the United States. 
In order to address this gap, the WSLH provides performance evaluation panels for 
select VPDs at no cost to PHLs who enroll in the programs. In the first 15 months of 
the project, WSLH provided four performance evaluation panels including a bacterial 
meningitis panel and measles and mumps panel. The measles and mumps panel 
yielded the greatest participation as a total of 47 PHLs participated in the fall 2013 
event. In the coming years and as funding allows, WSLH will offer a measles and 
mumps panel in both the fall and spring. 
22
Microbiologist Tonya Danz putting a tray into the PCR
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Figure 8: Schematic of VPD results to CDC via HL7 2.5.1 Messaging
Messaging of VPD Test Results
One of the other goals in establishing the VPD Reference Centers, was to develop the 
capability for real-time reporting of laboratory results to CDC to aid CDC in their ability 
to monitor VPD cases and rapidly identify outbreaks. The four VPD Reference Centers 
have used the standardized Health Level Seven International (HL7) Electronic Laboratory 
Reporting (ELR) as described in the ELR Guide 2.5.1 message guide to send standardized 
VPD results and applicable genotype data to CDC laboratories. 
The APHL Technical Assistance Team works with each laboratory to map local Laboratory 
Information Management System (LIMS) codes to standardized codes and to build the 
technical architecture needed for the electronic laboratory surveillance message (ELSM) 
data exchange with CDC. When a VPD result is finalized, the data is automatically made 
available in the LIMS, and if necessary, is transformed in an integration engine and used to 
generate the HL7 message that is sent automatically to CDC (Figure 2).
Currently, the reference laboratories are sending ELSM for seven of the eight VPD conditions. 
Since April 2013, the Reference Centers have been submitting real-time data to CDC via 
secure FTP site. In September 2013, they started submitting HL7 ELR 2.5.1 ELSM to CDC 
for measles, mumps, rubella and pertussis. Capability to message Varicella-zoster Virus, 
Streptococcus pneumoniae and Haemophilus influenzae results was added in June 2014. 
The Bacterial VPD Reference Centers are currently working on building the capacity to 
message Niesseria meningitidis results to CDC. It is anticipated that this will be complete by 
June 2015. Figure 8 illustrates the route of the results message from the Reference Center 
to CDC and submitter.  
Next Steps
Transmission electron micrograph of varicella-zoster 
virions from vesicle fluid of patient with chickenpox. 
Credit: CDC/Dr. Erskine Palmer 
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The VPD Reference Centers have been successful in their primary goal of increasing access 
to quality molecular testing for eight VPDs and have proven to be of great utility in meeting 
the needs of diagnostic surge capacity and increased access to performance evaluation 
panels. In the coming year, the Reference Centers plan not only to maintain capacity for 
molecular testing, but also make continuous improvements and enhancements to existing services. 
• In 2015, CDC and APHL plan to work with the Reference 
Centers to collect data on the performance of existing 
serological and molecular tests for measles and mumps 
in order to improve recommendations on which tests 
should be used in laboratories and ordered by clinicians. 
• A routine schedule for performance evaluation panels 
will be established and publicized allowing laboratories 
utilizing this service to better plan their quality 
assurance activities.
• In the spirit of continuous quality improvement, APHL 
fielded a customer satisfaction survey to VPD Submitting 
Sites and Epidemiologists in December 2014. APHL and 
CDC will work together to address any areas for possible 
improvement or any gaps in services.
• By June 2015, results for all eight VPDs tested for at 
the Reference Centers will be electronically transmitted 
to CDC. APHL will explore improvements to results 
messaging and enrollment services including establishing 
online enrollment and investigating the feasibility of 
instituting electronic results reporting to submitters. 
For more 
information, see 
the APHL VPD 
Information Sheet 
in Appendix A 
for more details 
on the project 
and accepted 
specimen types. 
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APHL/CDC VPD REFERENCE CENTERSASSOCIATI0N OF PUBLIC HEALTH LABORATORIES 
APHL/CDC Vaccine Preventable 
Disease (VPD) Reference Centers 
Who are the VPD Reference Centers?
The VPD Reference Centers are four public health laboratories that were selected through a competitive process 
to perform testing for eight VPDs using standardized methods developed by the Centers for Disease Control and 
Prevention (CDC). The Reference Centers work closely with APHL and CDC to provide quality testing to other public 
health laboratories and public health departments free of charge. The Reference Centers include:
•	 California Department of Public Health Laboratory provides measles, mumps, rubella, and varicella-zoster virus 
real time RT-PCR and genotyping
•	 Minnesota Public Health Laboratory Division provides measles, mumps, rubella, and varicella-zoster virus real 
time RT-PCR and genotyping as well as B. pertussis, S. pneumoniae, H. influenzae, N. meningitidis detection PCR 
and molecular serotyping/serogrouping
•	 New York State Department of Health: Wadsworth Center provides measles, mumps, rubella, and varicella-zoster 
virus real time RT-PCR and genotyping
•	 Wisconsin State Laboratory of Hygiene provides measles, mumps, rubella, and varicella-zoster virus real time 
RT-PCR and genotyping as well as B. pertussis, S. pneumoniae, H. influenzae, N. meningitidis detection PCR and 
molecular serotyping/serogrouping
Submitting sites are assigned to one or two of the VPD Reference Centers depending on the services requested. If 
you forget the Reference Center(s) to which you are assigned, please contact Laura Kovach (laura.iwig@aphl.org). 
What testing is available at the VPD Reference Centers?
Table 1: Vaccine Preventable Diseases Reference Center Test Menu
Viral Diseases real time RT-PCR Serology Genotyping Maximum Turn Around Times
Measles  
PCR: 2 days
Genotyping: 10 Days
Mumps  
Rubella  
Varicella-zoster  
Bacterial Diseases real time PCR Serology Serotyping/Grouping Maximum Turn Around Times
B. pertussis  
PCR: 2 Days
Serology: 5 Days
Serotyping/grouping:5
Days
S. pneumoniae  
N. meningitidis  
H. influenzae  
Genotyping: Genotyping will be performed on all PCR positive specimens unless otherwise indicated as a part of a 
larger outbreak. S. pneumoniae: At this time the Bacterial VPD Reference Centers will only accept S. pneumoniae 
specimens	or	isolates	from	children	≤5	years	old	with	history	of	vaccination	(PCV13	or	PPSV23).
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How are VPD Reference Center results reported?
The VPD Reference Centers should not alter the communication channels between the submitting laboratory and 
their jurisdictional epidemiologists. The VPD Reference Centers will receive specimens and perform the appropriate 
tests,	with	anticipated	turn-around-times	as	listed	in	Table	1.	Results	will	be	reported,	with	patient	identifiers,	by	
the Reference Laboratory to the submitting site through secure web portal, encrypted email, secure fax or over the 
phone. Results for all specimens tested will be reported to CDC by the Reference Laboratory via electronic HL7 
messaging	or	a	secure	FTP	site;	however,	these	data	will	not	replace	state	notifications	to	CDC	through	the	Nationally	
Notifiable	Diseases	Surveillance	System	(NNDSS),	which	should	be	submitted	per	the	usual	protocol.	
For more information visit: www.aphl.org/aphlprograms/infectious/emerging/Pages/re-emergence.aspx or contact 
Laura Kovach, senior specialist, infectious disease programs, 240.485.3831 or 
laura.iwig@aphl.org.
Table 2: Vaccine Preventable Diseases Reference Center Specimen and Shipping Recommendations
Viral Disease Assay Specimen Type Min. Specimen Volume Specimen Storage Shipping Recommendations
Measles real time RT-PCR
•	 Throat Swab in VTM
•	 Nasopharyngeal Swab in VTM
•	 Combined Throat/
Nasopharyngeal Swab in VTM
•	 Urine 
250µl
Place swabs in 2mL 
standard viral transport 
media.  Store at 4°C and 
ship within 24 hours. If 
shipping is delayed, store 
at -70°C.
Ship on cold packs if shipping within 
24 hours otherwise ship frozen.Mumps real time RT-PCR
•	 Buccal Swab in VTM
•	 Nasopharyngeal Swab in VTM
•	 Throat Swab in VTM
Rubella real time RT-PCR •	 Throat Swab in VTM
•	 Nasopharyngeal Swab in VTM
Varicella-zoster virus real 
time RT-PCR
•	 Skin Lesion Swab
•	 Scab
N/A Store at room temperature Ship scabs and lesion swabs at ambient temperature
*Swabs must be synthetic.  Do NOT use cotton swabs for viral specimen collection
Bacterial
Disease Assays
Specimen Type Min. Specimen 
Volume Specimen Storage Shipping Recommendations
B. pertussis
Real time PCR 
•	 Nasopharyngeal swab or isolate 600µl
Swabs should be 
refrigerated at 4°C 
as soon as possible.  
Isolates should be stored 
refrigerated in Regan-
Lowe transport medium 
or frozen on cryobeads
Refrigerated specimens should 
be shipped on cold packs. Frozen 
specimens should be shipped on 
dry ice.  
B. pertussis serology •	 Serum        500µl
Serum should be 
separated and 
refrigerated at 4°C within 
24 hours of collection 
and can be stored for 
up to 7 days. If stored 
for longer than 7 days, 
serum should be frozen 
at -20°C
Refrigerated specimens should 
be shipped on cold packs. Frozen 
specimens should be shipped frozen 
on dry ice.
S. pneumoniae 
Real time PCR or serotyping
•	 CSF; or 
•	 Isolate 250µl Primary specimen should 
be frozen. Isolates 
should be transported on 
chocolate agar slants or 
frozen stock and stored 
at ambient temperature.
Isolates can be shipped at ambient 
temperature. Frozen primary 
specimens or isolates should be 
shipped on dry ice.
N. meningitidis PCR and 
Serogrouping 
•	 CSF; or 
•	 Isolate 500µl
H. influenzae 
•	 CSF; or 
•	 Isolate 500µl
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promoting effective programs and public policy, APHL strives to provide public health 
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residents and to prevent and control disease globally.
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